Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Anlotinib + Sintilimab
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Anlotinib AL3818|AL-3818|AL 3818 FGFR Inhibitor (Pan) 26 KIT Inhibitor 57 PDGFR Inhibitor (Pan) 30 RET Inhibitor 52 VEGFR2 Inhibitor 37 VEGFR3 Inhibitor 6 Anlotinib (AL-3818) inhibits KDR (VEGFR2) and VEGFR3, FGFR1-4, PDGFRA/B, KIT, and RET, which may inhibit angiogenesis and tumor cell growth (PMID: 27716285, PMID: 32547218, PMID: 32724339).
Sintilimab IBI308|Tyvyt Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 117 Sintilimab (IBI308) is a monoclonal antibody that targets PD-1 (PDCD1), potentially resulting in enhanced anti-tumor immune response (PMID: 29300693, PMID: 29900038, PMID: 32656988).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive cervical cancer predicted - sensitive Anlotinib + Sintilimab Phase II Actionable In a Phase II study, a combination of Anlotinib (AL-3818) and Sintilimab (IBI308) resulted in an objective response rate of 54.8% (23/42, 2 complete responses and 21 partial responses) in CD274 (PD-L1)-positive recurrent or metastatic cervical cancer patients, and led to a disease control rate of 88.1% (37/42, 14 with stable disease), a median progression-free survival (PFS) of 9.4 mos and a 6-mo PFS rate of 73.1%, a median overall survival (OS) not reached, and a 12-mo OS rate of 73.8% (PMID: 35192397). 35192397
CD274 positive cervical squamous cell carcinoma predicted - sensitive Anlotinib + Sintilimab Phase II Actionable In a Phase II study, a combination of Anlotinib (AL-3818) and Sintilimab (IBI308) resulted in a significantly higher objective response rate in CD274 (PD-L1)-positive cervical squamous cell carcinoma patients compared to non-squamous cell cervical cancer patients, 69.7% (23/33) versus 0% (0/6), respectively (P=0.003), and longer median progression-free survival, 11.1 months vs 5.8 months, respectively (P=0.01) (PMID: 35192397). 35192397
FGFR3 Y373C bladder urothelial carcinoma predicted - sensitive Anlotinib + Sintilimab Case Reports/Case Series Actionable In a clinical case study, a patient with metastatic bladder urothelial cancer harboring FGFR3 Y373C, PIK3CA E542K and TP53 R213* who had previously progressed on combination treatment with Sintilimab (IBI308) and Abraxane (nab-paclitaxel), achieved a partial response after 3 cycles of combination treatment with Sintilimab (IBI308) and Anlotinib (AL-3818), and stable disease has been observed for over 11 months (PMID: 34109111). 34109111

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries


Additional content available in CKB BOOST